作为国内中医药产业头部企业，步长制药紧跟政策导向，近年来不断寻找出海突破，使"中国处方"既成 为国际医疗选项，更演变为东方哲学的价值载体。 五部门指导意见赋能 步长制药中药出海驶入"加速度" 目前，步长制药有超过170个产品（含独家和非独家）进入了2025版国家医保目录。独家产品数量为73 个（中成药占63个、化学药占9个、疫苗占1个），步长制药的1类新药注射用艾帕依泊汀α和首款生物 类似药阿达木单抗注射液正在加速冲刺，公司的创新转型不断提速，在产品创新、国际化布局、技术升 级等业务领域持续突破。 如今，从传统制造业的"产品输出"到高端产业的"技术标准输出"，从单一贸易的"走出去"到全球化运营 的"走进去"，中国企业的海外征程已迈入2.0时代。在这其中，中医药作为承载数千年中华文明的独特 产业名片，其企业出海既是文化软实力的具象延伸，更是我国在全球健康产业格局中抢占标准制定权与 价值链顶端的关键战略支点。 近日，山东步长制药股份有限公司控股子公司四川泸州步长生物制药有限公司（以下简称"泸州步长"） 与马来西亚公司MEDISPEC (M) SDN BHD（以下简称"MEDISPEC"）签署《独家供应协议》。根据 ...

如今，从传统制造业的"产品输出"到高端产业的"技术标准输出"，从单一贸易的"走出去"到全球化运营 的"走进去"，中国企业的海外征程已迈入2.0时代。在这其中，中医药作为承载数千年中华文明的独特 产业名片，其企业出海既是文化软实力的具象延伸，更是我国在全球健康产业格局中抢占标准制定权与 价值链顶端的关键战略支点。 目前，步长制药有超过170个产品（含独家和非独家）进入了2025版国家医保目录。独家产品数量为73 个（中成药占63个、化学药占9个、疫苗占1个），步长制药的1类新药注射用艾帕依泊汀α和首款生物 类似药阿达木单抗注射液正在加速冲刺，公司的创新转型不断提速。业绩增长的背后，是公司在产品创 新、国际化布局、技术升级等业务领域的持续突破。 近日，山东步长制药股份有限公司控股子公司四川泸州步长生物制药有限公司（以下简称"泸州步长"） 与马来西亚公司MEDISPEC (M) SDN BHD（以下简称"MEDISPEC"）签署《独家供应协议》。根据协 议，泸州步长将授权MEDISPEC作为马来西亚（目标区域）内独家代理商，负责注射用Efparepoetin alfa （目标产品）在该区域的注册、推广、分销及销售事 ...

Core Viewpoint - The company is facing a lawsuit related to a contract dispute involving approximately 652 million yuan, which may impact its inventory valuation and future profits [1] Group 1: Legal Issues - The company's subsidiary, Shanghai HePu, has filed a lawsuit against Jiemai Shanghai due to a contract dispute over the distribution agreement, with the court accepting the case [1] - The lawsuit involves around 550 million yuan worth of inventory that has not been transferred, posing a risk of inventory impairment [1] Group 2: Financial Performance - The company has experienced a decline in revenue for four consecutive years, with revenues of 160.07 billion yuan in 2020 dropping to an estimated 110.06 billion yuan in 2024 [2] - In the first three quarters of 2025, the company reported total revenue of 8.469 billion yuan, a slight decrease of 0.54% year-on-year, while net profit increased significantly by 177.54% to 868 million yuan [4] Group 3: Strategic Developments - The company plans to acquire six health food products for 7.5 million yuan to expand its presence in the health industry [5] - The acquisition involves obtaining the technical ownership of the products from six different independent entities, ensuring commercial production [6] Group 4: Market Performance - As of December 29, the company's stock price decreased by 1.16% to 16.26 yuan per share, with a total market capitalization of approximately 17.147 billion yuan [6]

近日，2025年第九届21世纪大健康产业竞争力研究「阳光」案例正式揭晓，步长制药凭借在药物 研发领域的持续突破与在社会公益事业的深耕践行，一举斩获"年度药物研发创新企业"与"年度优 秀公益企业"两项重磅荣誉。 作为大健康产业极具权威性的年度评选，「阳光」案例由数字化智库型财经媒体领跑者《2 1 世 纪 经 济 报 道 》 与 2 1 世 纪 新 健 康 研 究 院 发 起 ， 历 经 九 年 沉 淀 已 成 为 行 业 高 质 量 发 展 的 " 风 向 标"。步长制药的双奖加冕，既印证了其在产业创新与社会责任领域的双重领先地位，也为医 药企业可持续发展提供了生动范本。 第 九 届 2 1 世 纪 大健康产业竞争力 ing t 研究 | 阳光 | 案例 DIE ESG实践 典 范 类 「阳光」年度优秀 必要要亦 * 步长制药 这一战略调整并非简单的业务扩张，而是基于医药产业发展趋势的精准预判。彼时，中国医 药行业正从"仿制药主导"向"创新药突破"跨越，在政策、技术、资本的推动下，创新药实现 快速发展。在这一进程中，步长制药始终与产业发展同频共振。 持 续 的 研 发 投 入 是 创 新 的 关 键 。 2 0 ...

近日，2025年第九届21世纪大健康产业竞争力研究「阳光」案例正式揭晓，步长制药（603858）凭借在 药物研发领域的持续突破与在社会公益事业的深耕践行，一举斩获"年度药物研发创新企业"与"年度优 秀公益企业"两项重磅荣誉。 作为大健康产业极具权威性的年度评选，「阳光」案例由数字化智库型财经媒体领跑者《21 世纪经济 报道》与21世纪新健康研究院发起，历经九年沉淀已成为行业高质量发展的"风向标"。步长制药的双奖 加冕，既印证了其在产业创新与社会责任领域的双重领先地位，也为医药企业可持续发展提供了生动范 本。 步长制药自成立以来，始终坚持以"聚焦大病种、培育大品种"为核心战略，依托脑心同治理论，成功打 造了脑心通胶囊、稳心颗粒和丹红注射液三个独家专利品种，形成了立足心脑血管市场、覆盖中成药传 统优势领域、聚焦大病种、培育大品种的立体产品格局。 未来，步长制药将布局大健康产业，以专利中药为基础，积极开拓化药、生物药、疫苗等领域，逐步构 筑起多维度竞争护城河。 研发驱动转型，构筑全产业创新壁垒 "年度药物研发创新企业"的荣誉，是步长制药三十余载深耕医药产业、以创新为核心发展引擎的必然结 果。 步长制药的创新基因，首 ...

Core Viewpoint - The Shaanxi Provincial Government has awarded the first prize in the Science and Technology Progress Award for 2024 to a key technology integration demonstration application related to the quality assurance and low-carbon production of Qin medicine resources, led by Zhao Chao, the chairman and president of Shaanxi International Business and Trade Institute [1] Group 1 - Zhao Chao is a key contributor to the project that focuses on the standardization of the "Nao Xintong Capsule" under the National Administration of Traditional Chinese Medicine, emphasizing quality control from raw materials to finished products [1] - The project has established a comprehensive quality control technology system for the production of Nao Xintong Capsules, ensuring consistency across production batches [1] - Shaanxi International Business and Trade Institute was founded in 1997 by Buchang Pharmaceutical and is a full-time private undergraduate institution approved by the Ministry of Education [1]

Group 1 - The article highlights the achievements of Zhao Buchang in the field of traditional Chinese medicine, particularly his contributions to the development of innovative products like brain-heart capsules and stable heart granules [2][4] - It emphasizes the ambition for high-quality development in traditional Chinese medicine, focusing on scientific, clinical, preventive, and economic values to support a healthy China [4][5] - The narrative reflects a commitment to delivering quality medicine to the public and leveraging high technology to enhance the traditional medicine industry, showcasing a vision for the future of Chinese medicine [5] Group 2 - The article mentions the "Step Chang Pharmaceutical 75 Blueprint," indicating a strategic plan for the company's future growth and expansion in the global market [4] - It underscores the importance of addressing cardiovascular diseases through the "brain-heart co-treatment" approach, marking a new era in healthcare [5]

Group 1 - The core viewpoint of the articles highlights the strategic move of the company in digital healthcare through its stake in POMDOCTOR LIMITED, which has successfully listed on NASDAQ, marking a significant step towards integrating traditional medicine with digital health solutions [1] - The company holds approximately 15% of POMDOCTOR LIMITED's total shares post-IPO, indicating a substantial financial investment and a commitment to the digital health sector [1] - The business model of POMDOCTOR LIMITED focuses on chronic disease management, covering areas such as hypertension, diabetes, and cardiovascular diseases, which aligns with the company's existing product portfolio [1] Group 2 - The company has engaged in a "cancellation-style buyback" strategy to reduce its share capital, accumulating nearly 1.8 billion yuan in buybacks since its listing in 2016, which reflects its commitment to enhancing shareholder returns [2] - The chairman of the company actively leads various charitable initiatives, investing significant resources in poverty alleviation, education support, and medical assistance, showcasing its dedication to social responsibility [2] - The company aims to drive future growth through a dual approach of continuous R&D and social responsibility, focusing on modernizing traditional Chinese medicine and fostering high-tech innovation in the industry [2]

Core Insights - The announcement of POMDOCTOR LIMITED's listing on NASDAQ marks a significant milestone for the company, enhancing its cash flow and shareholder return capabilities [1] - The transformation of the company is not merely an addition of product categories but involves a strategic focus on high-value patented areas and a robust R&D pipeline [2] - The company has committed to social responsibility through extensive public welfare initiatives, which complement its capital strategies aimed at enhancing shareholder value [3][5] Group 1: Financial and Market Developments - The company holds approximately 15% of POMDOCTOR LIMITED's total shares post-IPO, indicating a strong financial position [1] - The company has increased its R&D investment from 512 million to 717 million RMB over three years, achieving a compound annual growth rate of about 18%, surpassing the industry average [2] - Cumulative share repurchases since 2016 amount to nearly 1.8 billion RMB, positioning the company as a leader in shareholder returns within the traditional Chinese medicine sector [3] Group 2: R&D and Product Development - The company has optimized its patent structure, with 474 effective patents and 17 new invention patents expected by 2025, supporting its innovation strategy [2] - The R&D pipeline includes 209 projects across traditional Chinese medicine, chemical drugs, biological products, and vaccines, indicating a comprehensive approach to product development [2] - The company is actively developing 12 biological products, with some already in the NDA application stage, and has four vaccine products available, with five more in development [2] Group 3: Social Responsibility and Community Engagement - The company has executed the "Together, Build China's Heart" public welfare project for 18 consecutive years, benefiting over one million people in Tibet and surrounding areas [3] - Initiatives include training for over 10,000 medical personnel and providing free surgeries for over 3,700 children with congenital heart disease [3][5] - The company has invested in local agricultural projects to support farmers, significantly improving their income and living standards [5]

Core Viewpoint - Hunan Fangsheng Pharmaceutical Co., Ltd. announced the completion of the Phase II clinical trial report for its innovative traditional Chinese medicine, Zhilong Tongluo Tablets, which is aimed at treating ischemic stroke recovery [1][2]. Group 1: Basic Information - Drug Name: Zhilong Tongluo Tablets - Dosage Form: Tablets - Research Type: Phase II Clinical Trial - Clinical Approval Number: 2011L01961 - Clinical Approval Date: November 5, 2011 - Cumulative R&D Expenditure: Approximately 13.566 million RMB (unaudited) [1]. - Indication: Aims to invigorate qi and blood, dispel stasis, and is suitable for treating symptoms related to ischemic stroke recovery [1]. Group 2: Clinical Research Details - The clinical trial was conducted at seven national drug clinical trial institutions across various provinces, with a total of 240 planned participants, of which 214 were actually enrolled [2][3]. - The trial design was randomized, double-blind, and included a placebo control, with participants divided into high-dose (7.5g/day), low-dose (4.5g/day), and placebo groups, receiving treatment for 12 weeks [3]. Group 3: Clinical Research Results - Efficacy results indicated that both high and low doses of Zhilong Tongluo Tablets showed better outcomes compared to the placebo in terms of the Modified Rankin Scale, NIHSS score changes, and quality of life measures [4]. - Safety results showed no significant differences in severe adverse events among groups, with all serious adverse events related to acute stroke recurrence, indicating good safety [4]. - The low-dose group is recommended to proceed to Phase III clinical research due to comparable efficacy with the high-dose group [4]. Group 4: Market Situation - Zhilong Tongluo Tablets are classified as a Class 1 innovative traditional Chinese medicine and are currently the company's exclusive product, with no other companies having obtained production approval for this product [5]. - Other traditional Chinese medicines for treating ischemic stroke include various products with significant sales figures, indicating a competitive market landscape [5].